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ABSTRACT
Background: Autism spectrum disorders (ASD) are a group of complex developmental
disabilities which can cause behavior, social, and communication deficits. Anti-psychotic
medications are often prescribed when symptoms such as aggression, irritability, hyperactivity,
tantrums, and self-injurious behavior occur.
Objective: To determine if anti-psychotic medications improve the behavior, social, and
communication symptoms associated with ASD in children and adolescents.
Search Strategy: Electronic literature searches were performed to find relevant studies and
utilized the (1) Cochrane Database of Systematic Reviews, (2) Hispanic American Periodicals
Index, (3) Medline, (4) PAIS International, (5) ProQuest Dissertations and Theses, (6) PsycInfo,
(7) PubMed, (8) Springer LINK, (9) Taylor and Francis Journals, and (10) Sage Premier.
Selection Criteria: Randomized controlled trials (RCTs) or quasi-experimental design (QED)
studies of any dose of an anti-psychotic medication compared to a placebo or other prescription
drug, in participants with autism spectrum disorder.
Data Collection and Analysis: All studies which met the full-text level criteria were reviewed
by a third party to validate the decision of inclusion. Meta-analyses in this review implemented
both random and fixed-effects models.
Main Results: Ten RCTs were included. Six studies evaluated a drug versus a placebo and four
studies investigated the effects of two separate anti-psychotic medications or the efficacy of an
additive medication to a drug and placebo group.
ii

Author’s Conclusions: Limited evidence suggests the effectiveness of anti-psychotic
medications in treating the behavior, social, and communication symptoms associated with
autism; however, further research is needed to determine the implications of long-term use.
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INTRODUCTION
Autism spectrum disorders (ASD) are a group of complex developmental disabilities that
result in behavior, social, and communication deficits. Recent data shows that 1 in 88 children
have an ASD (CDC, 2012). However, the number of cases of autism appears to be rising. It is
not yet clear whether this occurrence is due to improved detection methods and reporting of
autism, an actual increase in the amount of cases, or a combination of both (Mayo Foundation for
Medical Education and Research, 2010).
There are five different categories of ASDs; autistic disorder (also called “classic”
autism), Asperger syndrome, pervasive developmental disorder not otherwise specified (PDDNOS), Rett syndrome and childhood disintegrative disorder. The American Psychiatric
Association's Diagnostic and Statistical Manual-IV, Text Revision (DSM-IV-TR) 1 provides
standardized criteria to assist in diagnosing ASD and is summarized as follows:
•

Autistic disorder: A person diagnosed with autistic disorder shows clinically significant
impairments in social and communication behaviors, as well as restricted, repetitive, or
stereotyped patterns of behavior. Beginning prior to 3 years of age, individuals with
autistic disorder display deficits or abnormal functioning in a minimum of one of the
following areas: (1) social interaction, (2) language as utilized in social communication,
or (3) symbolic or imaginative play (American Psychiatric Association [APA], 2000).

•

Asperger syndrome: Individuals with Asperger syndrome generally exhibit milder
symptoms of autistic disorder. They may have social deficits and display repetitive
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behaviors. However, those with Asperger syndrome do not typically display severe
language or cognitive deficits (APA, 2000).
•

Pervasive developmental disorder not otherwise specified: Those who do not meet all of
the criteria for autistic disorder or Asperger syndrome due to atypical or sub-threshold
symptomatology or late age of onset may be diagnosed with PDD-NOS. (APA, 2000).

•

Rett syndrome: This condition primarily affects girls. It was recently discovered that Rett
syndrome is caused by mutations in the methl-CpG-binding protein 2 (MeCP2) gene
(Amir & Zoghbi, 2000). Males born with this defective gene do not have a second X
chromosome to compensate for the mutation (NINDS, 2011). Consequently, the defect
often results in miscarriage, stillbirth, or premature death. Since females have two X
chromosomes, the other X chromosome is normal enough for the child to survive. Those
with Rett syndrome show typical perinatal and psychomotor development. However, at 5
to 30 months of age individuals experience the loss of previously acquired purposeful
hand skills and the onset of severely impaired expressive and receptive language
development and clinically significant psychomotor regression (APA, 2000).

•

Childhood disintegrative disorder: A condition in which children develop normally
before age 10, after which, children may lose language, motor, social, and other skills
they previously acquired (APA, 2000).
There is currently no single gene or genetic test that definitively diagnoses autism (El-

Fishawy & State, 2010). The diagnosis of autism remains primarily based on clinical observation
and assessment of neurological, cognitive, and language abilities. A first step often includes a
questionnaire or other screening instrument to collect information about a child’s development
2

and behaviors (NINDS, 2012). Some screening instruments depend entirely on parent
observations, while others utilize a combination of parent, physician, and other professional’s
reports and observations. If the screening shows the possibility of an ASD, a more
comprehensive evaluation is recommended including a complete neurological, cognitive, and
language assessment (NINDS, 2012).
Social interaction issues are some of the most common deficits associated with ASD.
These symptoms often include avoidance or hypersensitivity to eye and physical contact, the
presence of neutral or inappropriate facial expressions, difficulty understanding the feelings of
others, and not understanding or recognizing personal space boundaries (CDC, 2010).
Communication deficits are frequently seen in individuals with ASD and manifested in
their difficulty in using or understanding gestures, and interpreting body language or tone of
voice (CDC, 2010). Developmentally, these communication issues can also include delayed
speech and language, repetition of words or phrases (echolalia), speaking in an unusual manner,
and use of idiosyncratic grammar (CDC, 2010).
Behavior issues can include hyperactivity, impulsivity, aggression, self-injury, and shortattention span. It is quite common for individuals with ASD to display hyper-organized
behaviors such as lining up objects or exhibit unusual interests or behaviors that are viewed as
obsessive interests or repetitive motions. Individuals with ASD may thrive on routine by
following a strict set of rituals. Any change in these types of routines or rituals can lead to severe
frustration or tantrums (CDC, 2010).
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There is currently no known cure for autism; however, the combination of behavioral
therapy, specialized therapies, and medication are commonly used to manage the symptoms of
ASD. Medications are frequently implemented when symptoms such as aggression, irritability,
hyperactivity, tantrums and self-injurious behavior occur but are not used to treat the core
symptoms of ASD. The classes of medications most frequently used to treat the behavioral
problems associated with ASD include anti-depressants, stimulants, mood stabilizers, and antipsychotics. Of these classes, anti-psychotic medications are the most commonly prescribed
medication for children with ASD (Cascade, Kalali & Feifel, 2008).
In 2006, the U.S. Food and Drug Administration approved risperidone, an anti-psychotic
drug intended for use with adults, for the treatment of irritability in children and adolescents with
autism. This general labeling of irritability also included treatment of behaviors such as
aggression, self-injury, and tantrums. The effectiveness of risperidone in the treatment of
irritability associated with pediatric ASD was examined in two 8-week, placebo-controlled trials
monitoring 156 patients aged 5-16 years of age. The results of this study were evaluated and
indicated that children treated with risperidone attained significantly improved scores for certain
behavioral symptoms associated with autism compared to children being treated with a placebo.
Only one study has been identified that assessed the efficacy of anti-psychotic
medications in treating the core features of ASD (Barnard, Young, Pearson, Geddes, & O’Brien,
2002). The study conducted by Barnard and colleagues reviewed 19 trials conducted between
1992 and 1999. Due to the limited number of studies, no restrictions were placed on the study
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designs within this review. The majority of studies focused on children between the ages of 4
and 18.
The studies contained a moderately homogenous group of patients who were severely
affected by their behaviors that were predominantly aggressive to self-injurious. Two studies
implemented a randomized, double blind crossover design with the remaining being prospective,
retrospective, or non-randomized. Thirteen studies examined the effects of risperidone, three
studies assessed olanzapine, and one study each investigated quetiapine, amisulpride, and
clozapine.
Barnard et al (2002) reviewed the effects of these medications on social functioning,
repetitive behaviors, language, aggression, hyperactivity, mood, and cognition. The studies
analyzed were characterized by a lack of blinding or randomization, an absence of systematic
and consistent measures among cases, and the use of small sample sizes, in addition to the use of
other medications. Barnard et al (2002) explained that much of the available research was based
upon case studies in which researchers may have been biased to only report those patients who
responded. The information gathered from these 19 included studies led Barnard and colleagues
to conclude that there was inadequate evidence to inform practice reliably and that well designed
randomized trials were needed.
Since the report performed by Barnard and colleagues (2002) there have been no
systematic reviews or meta-analyses that assess the efficacy of anti-psychotic medications in
treating the common behavioral issues associated with ASD in children or adolescents. Thus, the
purpose of this study was to conduct a systematic review and meta-analysis to determine the
5

efficacy of anti-psychotic medications in treating the behavior, social, and communication
deficits associated with ASD in children and adolescents and thereby add to the body of
knowledge currently available on the topic. This study sought to advance the review performed
by Barnard and colleagues by expanding the (1) number of databases accessed in the information
retrieval process, (2) the chronological dates used in the information retrieval process, (3) the
data analysis to include a quantification of the treatment effects using meta-analytic procedures,
and (4) expanding beyond English language only databases.
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METHOD
Search Strategy
Electronic literature searches were performed to find relevant studies and utilized the (1)
Cochrane Database of Systematic Reviews, (2) Hispanic American Periodicals Index, (3)
Medline, (4) PAIS International, (5) ProQuest Dissertations and Theses, (6) PsycInfo, (7)
PubMed, (8) Springer LINK, (9) Taylor and Francis Journals, and (10) Sage Premier. To locate
pertinent studies the search terms were categorized and combined according to:
Diagnostic: ‘autism’, ‘anti-psychotic’, ‘children’, ‘adolescents’
Symptom: ‘atypical’, ‘behavior’, ‘social’, ‘communication’, ‘speech’, ‘intervention’
Drug Treatment: ‘medication’, ‘trial’, ‘ risperidone’, ‘aripiprazole’, ‘haloperidol’, ‘olanzapine’,
‘thioridazine, ‘quetiapine’, ‘ clozapine’
Study Design: ‘randomized controlled trial’, ‘quasi-experimental design trial’
Inclusion Criteria
Decisions for studies to be included were made at two levels; (1) title and abstract
retrieval, and (2) full-text retrieval. Studies included at the title and abstract retrieval level must
have met the following criteria in order to advance to the full-text retrieval stage; (1) the use of
anti-psychotic medications in treating behavioral outcomes, and (2) participants must have been
under 18 years of age. Any title or abstract meeting these conditions advanced to the full text
retrieval stage in which a complete manuscript of each study was obtained and evaluated for
7

inclusion criteria including; (1) the person receiving treatment must have been clinically
diagnosed with autism, Asperger syndrome or PDD-NOS, (2) the treatment must have included
anti-psychotic medications in treating the behavior, social, or communication issues of children
and adolescents, (3) participants must have been between 2 and 18 years of age, (4) there must
have been a minimum of three participants included within the clinical trial, and (5) the study
must have used a randomized controlled trial or quasi-experimental research design.
Study Coding
All studies which met the full-text level criteria were reviewed by a third party to validate
the decision of inclusion. The coding of each included study was performed independently by
two coders. Once both coders completed the coding for a study, they compared the coding
conclusions. If there were any differences in coding judgments, the differences were discussed to
reach a consensus on the coding decision. In the event they were unable to reach a consensus, a
third coder evaluated the study and made a final decision. Every article included was coded to
determine the reporting of the variables listed below. A codebook was created to provide
definitions of each item on the coding form and is located in Appendix B.
Participant Characteristics: The participants for this review must have had a primary clinical
diagnosis of autism, Asperger syndrome, or PDD-NOS. Studies involving participants diagnosed
with Rett syndrome or childhood disintegrative disorder were not included. Participants must
have been between the ages of 2 and 18 years.
Treatment Characteristics: Only psychopharmaceutical interventions to treat the behavior, social,
or communication deficits associated with ASD were used as the treatment agent. There were no
8

restrictions regarding the duration of clinical trial, frequency of medication administration, or
dosage of medication(s).
Outcomes Characteristics: The behavior outcomes of interest were those related to aggression,
tantrums, self-injurious behaviors, repetitive tendencies, hyperactivity, and irritability. The social
outcomes of interest were those related to social withdrawal and social responsiveness. The
communication outcomes of interest were those associated with speech, language, and nonverbal
communication. Studies that assessed the physiological outcomes of pharmaceutical intervention
(e.g., metabolic changes, weight gain, prolactin levels, etc.) were not included.
Design Characteristics: Only randomized controlled trials and quasi-experimental design trials
were included in this review. Studies utilizing a single subject, prospective or retrospective
research design were excluded.
Data Calculation
Since the outcome data of included studies was presented in varying formats,
Comprehensive Meta-Analysis (CMA) (Borenstein, Hedges, Higgins & Rothstein, 2005)
software was used to analyze the treatment effect sizes. This software is capable of accepting
data in more than 100 different formats in order to convert it to a common effect size and
variance.
Effect Size Calculations

The appropriate formula, in CMA (Borenstein et al., 2005) was used to calculate a
standardized mean difference with a small sample size correction (Hedges’ g). The calculation of
9

the treatment effect was based on the mean difference between the treated and comparison
groups, accounting for the variance of measurement associated with participant performances.
The basic formula is as follows:

g=

TXmean - CTLmean
______________
SDpooled groups

When means and standard deviations were not provided, treatment effects were
calculated using the standard effect size formulae for F-Test, t-test, or p value. All reported
values were based on a calculation of Hedges’ g and were interpreted according to standards
provided by Cohen (1988): small effect = 0.0 to .20; medium effect = 0.20 to 0.70; large effect =
0.70 or greater.
Synthesis of Effect Sizes

Using the standardized mean difference (i.e., Hedges’ g), the effect sizes from each study
were weighted by the inverse variance and averaged to create an overall study effect size. If a
study reported more than one outcome for the same “treatment vs comparison group”
comparison only a single effect size was included in the meta-analysis for any outcome measure.
If a study involved more than two groups only the “treatment vs control group” comparison was
used to create a single effect size for the study.
Homogeneity Analysis
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A homogeneity analysis was applied to examine whether the differences in a set of effect
sizes may be considered a result of sampling error and/or a result of other participant and study
factors. Data synthesis for this study was conducted using both a random and fixed effects
model.
In order to allow for the widest application of the available data, a random effects model
was used for all data interpretations and conclusions. In the random effects procedure, the metaanalyses provides effect size estimates that vary across studies as a result of variations among the
study population parameters such as age, severity of behavior, as well as errors associated with
the sampling of participants within the study populations. Thus, the results from a random effects
model provides for an accounting of these variations to allow for a generalization of findings to
the population represented by the studies sampled for this review and analysis (Kline, 2004).
Publication Bias

To assess potential publication bias, the trim and fill procedure was applied. The analysis
is provided in the resulting funnel plot (Rothstein, Borenstein, and Sutton, 2005).
Sensitivity Analysis

The one study removed analysis examined the impact of a single study effect size on the
overall effect size for any outcome with multiple studies measuring the same outcome. The
procedures involved the removal of the effect size for a single study, recalculation of the average
overall effect for the remaining studies, then removal of the next study effect size while replacing
the previous study effect size to calculate the overall treatment effect. This method allowed for a
11

more precise picture of the contribution of each study to the overall treatment effect results, such
that, those studies with larger sample sizes were given proportionately more weight than studies
with small samples sizes when estimating the average effect size in any calculation.
Moderator Analyses

Moderator analyses were performed to assess differences in the average effect sizes for
the following study-level characteristics; (1) socioeconomic status, (2) sample source, (3)
participant severity, and (4) participant ethnicity/race. The moderator analyses were conducted
using the fixed effects model.

12

RESULTS
Search Results

Initial Search: 340 references
Excluded: 314 references
Not relevant from title/abstract
(n=314)

Full Text Retrieval: 26 references

Study Inclusion: 10 references

Excluded: 16 references
Monotherapy Design (n=5)
Maintenance Design (n=4)
Prospective design (n=5)
Retrospective design (n=1)
Participant diagnosed with CDD
(n=1)

Figure 1: Flowchart of search results

The initial search identified 340 studies. Of these, 314 were excluded as not relevant
based on titles or abstracts. The remaining 26 studies were evaluated after retrieval of the full
text. Upon review of the 26 studies, 16 studies were excluded for the following reasons. One
study; Shea et al. (2004), was excluded in the analysis stage due to the author’s inclusion of
participants diagnosed with childhood disintegrative disorder. A total of five studies were
excluded due to a monotherapy design (Nicholson, Awad, & Sloman, 1998; Findling, Maxwell,
& Wiznitzer, 1997; McDougle et al., 1997; Perry et al., 1997; Martin et al., 1999). Four studies
were excluded due to utilization of a discontinuation/continuation maintenance study design
(Gencer et al., 2007; McCracken et al., 2005; Troost et al., 2005; Marcus et al., 2011). Five
13

studies were excluded due to the utilization of a prospective case series study design (Fisman &
Steele, 1996; Hardan, Johnson, & Hrecznyj, 1996; Malek-Ahmadi & Simonds, 1998; Horrigan,
Barnhill, & Courvoise, 1997; Zuddas et al., 1996). Lastly, a study by Posey et al. (1999) was
excluded due to a retrospective case series study design. Ten studies met the inclusion criteria to
be analyzed in this review. Table 1 shows the characteristics of participants within these studies.
While this review allowed for both RCT and QED study designs the ten studies which met
inclusion criteria all utilized a RCT design.
Table 1: Characteristics of participants

Study
Name
Dollfus
McCracken
Nagaraj
Pandina
Luby
Miral
Akhondzadeh
Owen
Marcus
Rezaei

Tx
n
5
49
19
20
11
13
20
46
47
20

Tx
Tx
Mean Tx
Mean
Age
%
Weight Com
(yrs) Male
(kg)
n
6.9
56%
NR
4
8.8
80%
NR
52
4.8
84%
16.2
20
7.4
70%
30.4
21
4.1
81%
19.2
11
10
73%
33.3
15
7.5
78%
26.2
20
9.7
89%
43.9
49
9.5
89%
43.1
38
8.2
65%
26.8
20

Com
Mean
Age
(yrs)
6.9
8.8
5.3
7.1
4
10.9
7.1
8.8
10.2
7.9

Com
%
Male
56%
83%
90%
86%
66%
87%
75%
86%
92%
70%

Com
Mean
Weight
(kg)
NR
NR
18.3
27.3
18.1
42.1
26
40.6
42.2
27.4

Overall Treatment Effect
An analysis of the general effects of anti-psychotic drug treatment was assessed by first
calculating an effect size for all outcomes in all 10 included studies to produce a single study
effect size. Next these effect sizes were averaged for each study to produce a meta-analysis of an
estimate of the overall treatment impact. Figure 2 displays the average effect of anti-psychotic
14

medications versus a comparison drug or placebo for all outcomes reported (g = 0.67, p = 0.000,
95% CI = 0.49 to 0.86). This analysis suggested that anti-psychotic medications appear to have a
statistically significantly positive effect on children and adolescents diagnosed with ASD to
improve the behavior, social, and communication outcomes.
A test of heterogeneity was calculated using a fixed effects model to evaluate the amount
of variation in study effect sizes beyond sampling error. The analysis resulted in a nonsignificant measurement of heterogeneity (Q = 6.516, df = 9, p = 0.719), suggesting that
variation in the effect sizes, and thus the treatment effect, can be attributed to factors other than
sampling error, namely the drug intervention. To further substantiate this finding the overall
analysis was subjected to a random effects model with the resulting g value, lower and upper
limits, and p value being identical to the fixed effects result. These findings support the
assumption that, in general, the observed effect sizes were drawn from a similar population and
generalizations are appropriate to all participants reported in the included studies and potentially
to similar studies not included in this review.
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Study Name Year Comparison

Outcome

Hedges’ Lower Upper p-Value Exp Comp
n
n
g
Limit
Limit

Dollfus

1992 Amisul v Bromo Combined

0.925

-0.346 2.215 0.160

5

4

McCracken

2002 Risp v Placebo Combined

0.576

0.180 0.972 0.004

49

52

Nagaraj

2005 Risp v Placebo Combined

0.889

0.242 1.536 0.007

19

20

Pandina

2006 Risp v Placebo Combined

0.637

-0.178 1.453 0.126

20

21

Luby

2006 Risp v Placebo Combined

0.302

-0.507 1.111

0.465

11

11

Miral

2007 Risp v Halp

Combined

0.549

-0.191 1.288 0.146

13

15

Akhondzadeh 2009 Combined

Combined

1.347

0.281 2.022 0.000

20

20

Owen

2009 Aripip v
Placebo

Combined

0.692

0.220 1.103 0.001

46

49

Marcus

2009 Aripip v
Placebo

Combined

0.656

0.217 1.092 0.003

47

38

Rezaei

2010 Risp+Topira v
Risp+Placebo

Combined

0.421

-0.197 1.039 0.182

20

20

0.674

0.493 0.856 0.000

Hedges’ g & 95% CI

-2.0
0.0
2.0
Favors Placebo Favors Drug

Q= 6.516, df= 9, p=.719

Figure 2: Overall treatment effect

Publication Bias Analysis
Publication bias addresses the possibility that the included studies, which are composed
of peer-reviewed publications, may result in an inaccurate measurement of the drug treatment
effect. To analyze potential publication bias a funnel plot of standard error by Hedges’ g was
created. Figure 3 shows that the ten studies conform to the shape of the funnel plot suggesting
one can be confident that the included studies constitute a representative sample of studies that
may have not been identified and included in this review. Furthermore, the trim and fill analysis
was then applied to the data, which trims exceptionally large studies and imputes small studies
16

that are purportedly missing. Under the fixed effect model the point estimate and 95%
confidence interval for the combined studies was 0.67 (95% CI = 0.49 to 0.86). Using the trim
and fill analysis these values remained unchanged. This symmetry suggests the absence of
publication bias.
A second publication bias analysis was also conducted by calculating the number of
studies that would have to exist and not be included in this review to significantly alter the
obtained treatment effect. This analysis revealed that a total of 123 studies with an average
treatment effect size of 0.0 would have to exist in order negate the current overall effect size of
0.67. That is, while it is possible that one or more studies may not have been identified that
would have met the inclusion criteria; these data suggest that it is reasonably unlikely additional
studies, if identified, would statistically alter the observed treatment effect in this review.
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Funnel Plot of Standard Error by Hedges's g
0.0

Standard Error

0.2

0.4

0.6

0.8
-2.0

-1.5

-1.0

-0.5

0.0

0.5

1.0

1.5

2.0

Hedges's g

Figure 3: Funnel plot of standard error by Hedges' g

Overall Treatment Effect: Drug versus Placebo
An analysis was performed to evaluate the overall effect size of anti-psychotic
medication treatment versus placebo treatment. Four studies were identified that examined the
efficacy of risperidone compared to a placebo treatment (McCracken et al., 2002; Nagaraj,
Singhi, & Malhi, 2005; Pandina et al., 2006; Luby et al., 2006) while two studies were identified
that investigated the efficacy of aripiprazole versus placebo treatment (Owen et al., 2009;
Marcus et al., 2009). All dependent variables were categorized into three major types of
18

outcomes: behavior, social, and communication. The following is a summary of the treatment
effects for each outcome category.
Overall Effect for Behavior Outcomes

Several behavior outcomes are represented in the summary data below (e.g.,
hyperactivity, irritability, stereotypic behavior, etc.). Table 2 provides a summary of both
treatment medications. Risperidone exhibited an overall effect of g = 0.67 (p = 0.000, 95% CI=
0.38 to 0.96) and Aripiprazole an overall effect of g = 0.65 (p = 0.000, 95% CI = 0.35 to 0.95). A
meta-analysis of all behavior outcomes across both drugs and all studies, resulted in a
statistically significant treatment effect of g = 0.66 (p = 0.000, 95% CI = 0.45 to 0.87) in favor of
the treated participants for both drug types.
Table 2: Overall effect for behavior outcomes

Study
Name
Luby
McCracken
Nagaraj
Pandina

Year

Drug

2002
2005
2006

Risperidone
Risperidone
Risperidone
Risperidone

Fixed Effects
Marcus
Owen

2009
2009

Fixed Effects

Hedges' Lower Upper
p-value Tx n
g
Limit Limit
0.288
-0.520 1.097
0.484
11
0.670
0.272 1.068
0.001
49
0.918
0.269 1.567
0.006
19
0.655
-0.206 1.516
0.136
18

Risperidone

0.669

0.375

0.963

0.000

Aripiprazole
Aripiprazole

0.599
0.692

0.165
0.281

1.034
1.103

0.007
0.001

Aripiprazole

0.648

0.350

0.947

0.000

Overall Effect for Social Outcomes
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47
46

Ctl n
11
52
20
20
38
49

The assessment of social outcomes (e.g., social withdrawal, social responsiveness, etc…)
was conducted in three studies, all using the anti-psychotic medication risperidone (McCracken
et al., 2002; Nagaraj et al., 2005; Pandina et al., 2006). A meta-analytic analysis revealed a
statistically significant improvement for the treated participants of g = 0.55 (p = 0.000, 95% CI =
0.26 to 0.83). Table 3 presents a summary of the effects associated with each study and an
overall aggregate of the treatment effect.
Table 3: Overall effect for social outcomes

Study
Name
McCracken
Nagaraj
Pandina

Year

Drug

2002
2005
2006

Risperidone
Risperidone
Risperidone

Hedges'
g
0.435
0.810
0.566
0.545

Lower Upper
Limit Limit
0.043 0.827
0.169 1.450
0.032 1.101
0.262 0.829

pValue
0.030
0.013
0.038
0.000

Tx n

Ctl n

49
19
27

52
20
28

Overall Effect for Communication Outcomes
The assessment of the treatment effects on communication outcomes (e.g., inappropriate
speech) was also performed in the same three studies as the social outcomes (McCracken et al.,
2002; Nagaraj et al., 2005; Pandina et al., 2006) and yielded a statistically significant treatment
effect of g = 0.55 (p = 0.000, 95% CI = 0.26 to 0.83). Table 4 presents a summary of the effects
associated with each study and the meta-analysis of the combined studies for the measurement of
social outcome effects.
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Table 4: Overall effect for communication outcomes

Study
Name
McCracken
Nagaraj
Pandina

Year

Drug

2002
2005
2006

Risperidone
Risperidone
Risperidone

Hedges'
g
0.435
0.880
0.520
0.545

Lower
Limit
0.043
0.235
-0.015
0.261

Upper
Limit
0.827
1.525
1.055
0.829

pValue
0.030
0.008
0.057
0.000

Tx n

Ctl n

49
19
26

52
20
28

Summary of Treatment Effects

Overall, risperidone had a statistically significant effect across studies on behavior (g =
0.66), social (g= 0.55), and communication (g = 0.55) outcome measures, suggesting improved
scores for these outcomes were due to the daily treatment intervention of risperidone.
Risperidone vs Placebo Effect as Moderated by SES

In order to assess the potential impact of specified independent variables on the
magnitude of the treatment effect, a moderator analysis was conducted for the variables of
socioeconomic status (SES), sample source, participant severity, and race/ethnicity. These
analyses were conducted under the fixed effects model with a non-significant Q value resulting
(p= 0.05). Table 5 illustrates the impact of SES on the effect of risperidone when compared to a
placebo. Two studies; McCracken et al. (2002) and Nagaraj et al. (2005), reported participants
from an SES group composed of Middle-Upper class participants. One study (Pandina et al.,
2006), provided no information regarding the SES of participants and another single study (Luby
et al., 2006), had an unclear definition of SES for group participants.
Due to the limited number of studies reporting socioeconomic status, it was not possible
to draw a reliable conclusion on the impact this factor had in the measured treatment effect of
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risperidone versus placebo. The treatment effect could suggest a potential finding in which
studies reporting less information on SES might exhibit smaller treatment effects.
Table 5: Risperidone versus placebo effect as moderated by SES

Study
Lower
Moderator
Name
Year Hedges's g Limit
Mid-Up
McCracken 2002
0.576
0.180
Mid-Up
Nagaraj
2005
0.889
0.242
Mid-Up
0.661
0.324
NR
Pandina
2006
0.637
-0.178
Unclear
Luby
2006
0.302
-0.507
Overall
0.612
0.321

Upper
Limit
0.972
1.536
0.999
1.453
1.111
0.903

p-Value
0.004
0.007
0
0.126
0.465
0

Tx n
49
19

Ctl n
52
20

20
11

21
11

Risperidone versus Placebo Effect as Moderated by Sample Source

The assessment of the moderator effect of the source from which the study sample was
drawn is presented in Table 6. Two studies reported no information as to the sample source
(Pandina et al., 2006 & McCracken et al., 2002) while one study indicated that the participants
were drawn from a clinic (Nagaraj et al., 2005) and another study where participants were drawn
from several different sources (Luby et al., 2006). Due to the small number of studies that
reported the source of their samples, an analysis of the overall effect of the sample was not
warranted or appropriate.
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Table 6: Risperidone versus placebo effect as moderated by sample source

Moderator
Clinic
Mixed
NR
NR
NR
Overall

Study
Name
Nagaraj
Luby
McCracken
Pandina

Year
2005
2006
2002
2006

Hedges's g
0.889
0.302
0.576
0.637
0.588
0.612

Lower Upper
Limit Limit
0.242 1.536
-0.507 1.111
0.180 0.972
-0.178 1.453
0.232 0.944
0.321 0.903

p-Value
0.007
0.465
0.004
0.126
0.001
0

Tx n
19
11
49
20

Ctl n
20
11
52
21

Risperidone versus Placebo Effect as Moderated by Participant Severity

A summary of the moderating effect of the participant severity reporting is presented in
Table 7. Since only a single study was represented for each of four different reporting levels of
participant severity, these data can only be understood as descriptive of the individual study. The
absence of multiple studies reporting information relative to participant severity when comparing
risperidone versus placebo treatment provided no useful information as to the potential impact of
participant severity on the magnitude of the treatment effect for any single severity rating.
Table 7: Risperidone versus placebo effect as moderated by participant severity

Moderator
Mix
Mod-Sev
NR
Sev
Overall

Study
Name
Luby
McCracken
Nagaraj
Pandina

Year Hedges's g
2006
0.302
2002
0.576
2005
0.889
2006
0.637
0.612

Lower Upper
Limit Limit
-0.507 1.111
0.180 0.972
0.242 1.536
-0.178 1.453
0.321 0.903

p-Value
0.465
0.004
0.007
0.126
0

Tx n
11
49
19
20

Ctl n
11
52
20
21

Risperidone versus Placebo Effect as Moderated by Participant Ethnicity/Race

Table 8 displays the effect of participant ethnicity/race in the efficacy of risperidone
versus placebo treatment. Three studies; Luby et al. (2006), McCracken et al. (2002), and
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Pandina et al. (2006), reported a mixed sample of participant ethnicity/race. The aggregated
effect across the studies was g = 0.61 (p = 0.000, 95% CI = 0.32 to 0.90). One study (Nagaraj et
al., 2005) did not report participant ethnicity/race and showed an effect size almost twice as large
as the other three studies reporting a mixed ethnic/racial representation. While the data are
sparse, the results do call into question the credibility of the effect size of the study not reporting
information regarding participant ethnicity/race given that the resulting effect is almost twice as
large as the other three studies combined.
Table 8: Risperidone versus placebo effect as moderated by participant ethnicity/race

Study
Moderator
Name
Mixed
Luby
Mixed
McCracken
Mixed
Pandina
Mixed
NR
Nagaraj
Overall

Year
2006
2002
2006
2005

Hedges’ g
0.302
0.576
0.637
0.541
0.889
0.612
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Lower Upper
Limit Limit p-Value
-0.507 1.111
0.465
0.180 0.972
0.004
-0.178 1.453
0.126
0.216 0.867
0.001
0.242 1.536
0.007
0.321 0.903
0

Tx n
11
49
20

Ctl n
11
52
21

19

20

CONCLUSION
The purpose of this systematic review and meta-analysis was to evaluate the efficacy of
anti-psychotic medications in treating the maladaptive behaviors associated with ASD in
children and adolescents. Electronic literature searches were performed to find relevant studies.
Ten clinical trials were found that met the inclusion criteria for this review. The meta-analysis in
this review implemented both random and fixed-effects models.
Six of the included studies investigated the effects of a drug versus a placebo and four
studies examined the effects of two separate anti-psychotic medications or the efficacy of an
additive medication to a drug and placebo group. Based on this selection of studies, an analysis
was performed to assess the causal effect of the drug treatments and the potential moderating
effect of selected independent variables. The following provides a discussion of the results and
conclusions to be drawn.
Overall Treatment Effect
Overall, anti-psychotic medications were shown to have a positive and statistically
significant effect on the behavior, social, and communication outcomes reported for children and
adolescents with ASD. The systematic review performed by Barnard and colleagues (1992) was
unable to inform reliably on the use of anti-psychotics due to the lack of RCTs available at the
time. However, based on this analysis, the overall effect size suggested that daily use of an antipsychotic medication for at least eight weeks improved the behavior, social, and communication
deficits associated with ASD.
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The aggregation of effect sizes across multiple studies using different medications,
varying treatment characteristics, and study design characteristics did not provide a clear
interpretation of the effects of any particular medication or treatment protocol. A more precise
interpretation can only be made when the studies that are combined are similar across one or
more important study features.
Risperidone Treatment Effect
Specifically, the results of the studies comparing risperidone to a placebo allowed for a
causal statement of the treatment effect and indicated that risperidone produced a positive and
statistically significant effect on behavior (g = 0.66), social (g = 0.55), and communication (g =
0.55) symptoms. These results suggest that, when treated daily with risperidone, children and
adolescents with ASD displayed an overall improvement on the measured treatment outcomes
(e.g., aggressiveness, social withdrawal, speech, and self-injury).
Overall Effect for Behavior Outcomes

An analysis of the overall effect for behavior outcomes also provided for a causal
statement of the overall treatment effect. When treated with risperidone compared to a placebo,
participants exhibited a positive and statistically significant effect on the behavior measures
utilized across studies (g = 0.66). This result suggests that, when treated daily with risperidone,
children and adolescents with ASD displayed an overall improvement on the measured behavior
outcomes (e.g., irritability, hyperactivity/noncompliance, etc.).
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Overall Effect for Social Outcomes

In relation to social outcomes, the data revealed that when treated with risperidone
compared to a placebo, participants demonstrated a statistically significant positive but moderate
effect on the social measures observed across studies (g = 0.55). This finding suggests that social
behaviors (e.g., social withdrawal, lethargy, social responsiveness, etc.) improved when children
and adolescents with ASD receive treatment daily with risperidone.
Overall Effect for Communication

The analysis of the overall effect for communication outcomes allows for a causal
statement of the overall treatment effect. When treated with risperidone compared to a placebo,
risperidone produced a statistically significant positive moderate effect on the communication
outcomes (g = 0.55). This result suggests that, when treated daily with risperidone, children and
adolescents with ASD displayed an overall improvement on the reported communication
outcomes (such as language skill and inappropriate speech).
Aripiprazole Treatment Effect
Two studies were identified and included in this review that investigated the efficacy of
aripiprazole in children and adolescents using a treatment vs placebo design (Owen et al., 2009
& Marcus et al., 2009). A meta-analysis was conducted and revealed an uneven reporting of
outcome performances that would allow for a substantial causal conclusion.
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Overall Effect for Behavior Outcomes
The meta-analytic analysis for two studies examining the efficacy of aripiprazole in
children and adolescents (Owen et al., 2009 & Marcus et al., 2009) also allow for a causal
statement of the impact of the drug treatment with an overall treatment effect size of g = 0.65.
Due to the small number of studies available comparing aripiprazole to a placebo condition, the
available data must be interpreted cautiously and is best understood as a descriptive estimate of
the treatment effect of the individual studies.
Overall Effect for Social Outcomes

The two studies (Owen et al., 2009 & Marcus et al., 2009) assessing the efficacy of
aripiprazole in treating children and adolescents did not report social outcome measures.
Therefore, an analysis of data could not be performed.
Overall Effect for Communication Outcomes

Owen et al., (2009) and Marcus et al. (2009) examined the efficacy of aripiprazole in
treating children and adolescents but did not report communication outcome measures.
Consequently, an interpretation of data could not be made.
Overall Effect of Moderator Variables

An analysis of the overall effect of moderator variables (i.e., SES, sample source,
participant severity, and participant race) illustrated that too few studies reported details such as
SES or participant race. As a result, an interpretation of the impact of these factors in a
risperidone versus placebo comparison could not be made.
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Limitations
There are several limitations to this study.
1. Only two studies observed the effects of anti-psychotic treatment for more than twelve weeks,
so while a majority of participants had a positive response to treatment, results of this study only
assess the short-term efficacy of anti-psychotic medications.
2. This review focuses on the behavior, social, and communication improvement of children and
adolescents with ASD and does not thoroughly examine the physiological implications of antipsychotic medication treatment.
3. This analysis excluded studies with a participant diagnosis of childhood disintegrative disorder
and Rett syndrome.
4. There were too few studies represented for any treatment medication other than risperidone to
support widespread application for use on children and adolescents with autism.
5. The reporting of potentially moderating variables was limited or absent in many studies
making any explanatory interpretation of the nature of the treatment impact limited.
Implications for Future Research
There is a need to enhance the research base through the use of RCT designed studies that
analyze the effects of individual anti-psychotic medications on behavior, social, and
communication skills through longer term trials and larger sample sizes. While it is apparent at
least two anti-psychotic medications have a generally positive impact on maladaptive behaviors,
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there is a lack of research investigating either the moderating variables that might contribute to
an explanation as to the critical variables impacting the treatment effect or the long-term
implications of routine anti-psychotic treatment. Do side effects of anti-psychotics subside over
time? Or, does long-term use worsen the potential side effects? Also, does long-term use lead to
drug tolerance and a need to increase daily dose over time?
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Coding
Number______
APA Citation:______
Publication Source:
1.
2.
3.
4.
5.
6.
7.
8.
9.

Journal Article
Conference Paper
Master Thesis
Organization Report
Technical Report
Doctoral Dissertation
Book or Book Chapter
Not Reported
Other________________________________

Funding Source (pg. ____ ):
Subject Characteristics (pg. ____ ):

Groups

Pretreatment
(n)

PostAttrition
Treatment (n)
(n)

Followup
(n)

Age
(years)

% male

T
(1)
T
(2)
C
(1)
C
(2)
Com
(1)
Com
(2)

Comments: ________________________________________________________________
SES (pg.____ )
1. Low

5. Middle-Upper
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2.
3.
4.
9.

Middle
Upper
Low-Middle
Not Reported

6. Labeled Mixed
7. Unclear
8. Other__________

Sample Source: (pg.____ )
1. Public School
2. Private School
3. Univ. Clinic / Outpatient Clinic

4. Not Reported
5. Unclear
6. Other__________

Comments:_________________________________________________

Setting (pg.____ )
1.
2.
3.
4.
5.

Urban
Suburban
Rural
Urban-Suburban
Urban-Rural

6.
7.
8.
9.

Suburban-Rural
Unclear
Other__________
Not Reported

Comments:_________________________________________________
Geographic Setting: __________________________________________

Author’s Labeling of Participants:
1. Autism
5. Not Reported

2. Asperger
3. PDD-NOS
6. Other______________________

4. Unclear

Severity of Participants Pre-test (pg. ____ )
1.
2.
3.
4.

Mild
Mild-Moderate
Moderate
Moderate-Severe

5.
6.
7.
8.

Severe
Unclear
Mixed
Not Reported

Comments: __________________________________________________
Education Level of Participants (pg. ____ ):
1. Pre-School

6. Clinic Only
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2.
3.
4.
5.

K-5
Middle School (6-8)
High School (9-12)
Homeschool

7. Unclear
8. Other__________
9. Not Reported

Race/Ethnicity (pg. ____ ):
1.
2.
3.
4.

African American
American Indian
Asian
Hispanic /Latino

5.
6.
7.
8.

White/Caucasian
Unclear
Mixed_______
Not Reported

Intervention Characteristics: (pg. ____ ):
1.
2.
3.
4.
5.
6.

Drug Name: ________________________
Dose: ________________________
Length of intervention (pg. ____ ): ____________________________
Frequency of treatments: __________________________
Treatment setting: ____________________________
Side effects: _____________________________

Outcome Measure(s): (pg. ____ )
1. Norm Referenced Test (pg. ____ )
_______________________________________________________________
Who administered the measure? (pg. ____ )
1. Physician/Researcher
2. Parents
3. Teacher Counselor/Clinician
Other_____________________

4. Unclear
5. Not Reported
6.

2. Criterion Referenced Test (pg. ____ )
_______________________________________________________________
Who administered the measure? (pg. ____ )
1. Physician/Research
4. Unclear
2. Parents
5. Not Reported
3. Teacher Counselor/Clinician
6.
Other_____________________
3. Rating Scale (pg. ____ )
_______________________________________________________________
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Who administered the measure? (pg. ____ )
1. Physician/Researcher
2. Parents
3. Teacher Counselor/Clinician
Other_____________________

4. Unclear
5. Not Reported
6.

Outcome Variables: (pg. ____ )
Design Characteristic: (pg. ____ )
Recruitment Pool (pg. ____ )
1.
2.
3.
4.
5.
6.

Referral
Criterion___________
Scores on Norm Referenced Test __________
Existing Group
Volunteer
Waiting List

4. Unclear
5. Not Reported
6. Other_________

Design Type (pg. ____ )
1. RCT
2. Quasi-Experimental
Subject Assignment (pg. ____ )
1.
2.
3.
4.

Individual Random
Whole Group Random
Individual Matched-Random
Matched Non-Random

6. Non-Matched Non-Random
7. Unclear
8. Not Reported
9. Other_____________________

Method of Random Assignment (pg. ____ )
1.
2.
3.
4.

Random Number Generation
Simple Random
Coin Flip
Unclear

4. Not Reported
5. Allocation/Assignment
6. Other__________

Type of Analysis (pg. ____ )
1. Intent to Treat
2. Treat Only
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Individual Blinding 1 (pg. ____ )
1.
2.
3.
4.
5.
6.
7.

Group Blinding 2 (pg. ____ )

Researcher (pg. ____ )
Participants (pg. ____ )
Intervener (pg. ____ )
Assessor (pg. ____ )
No Blinding
Unclear
Not Reported

Two Groups
Compared
Outcomes
Groups
Mean
SD
N at Posttest
N at Follow-up 1
N at Follow-up 2
N at Follow-up 3
d-index
F value
t value
p value

1.
2.
3.
4.

Group 1:

Exp

Open
Single Blind
Double Blind
Triple Blind

Group 2:

Ctl

Exp
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Ctl

Exp

Ctl
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Publication Source
Journal article - An article published in a periodical devoted to a particular subject matter; can be
peer or non-peer reviewed.
Conference paper - An original paper submitted and/or presented at a formal conference.
Master thesis - A paper on a specific subject of original research by a candidate for a diploma or
degree.
Organization report - A paper describing results of a study that was performed for a government
agency, private foundation, or corporate group.
Technical report - A paper that explains the progress or results of technical or scientific research;
usually not peer reviewed.
Doctoral dissertation - A paper on a specific subject of original research by a candidate for a
degree or professional qualification.
Book or book chapter - A printed work of nonfiction.
Not Reported - The format of publication was not reported.
Other - A paper or article of any format other than those presented here.
Subject Characteristics
Control - A group of subjects used for comparison in a scientific experiment.
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Experimental - A group of subjects used in an experiment to perform a test and an independent
variable is applied (e.g., treatment).
Attrition - A reduction in participants assigned to either experimental or control conditions.
SES (socioeconomic status)
An individual's or group's position within a hierarchical social structure. The author’s/authors’
designation of one of the following:
Low
Low-middle: includes reference to both low and middle levels of SES
Middle
Middle-upper: includes reference to both middle and upper levels of SES
Upper
Labeled mixed: includes reference to all levels of SES or a non-specific reference to a multilevel SES representation (e.g., “…. participants represented all levels of SES).
Unclear: A statement that does not explicitly indicate the SES of participants obtained.
Other: A SES other than those presented here.
Not reported: The SES of participants was not reported.

Sample Source
The organization from which participants were obtained before group assignment.
School - A public or private institution in which instruction is given.
Clinic - A facility; often affiliated with a hospital, university, or a private practice, that is
committed to the diagnosis and treatment of outpatients.
Not reported - The origin of the sample source was not reported.
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Unclear - A statement that does not explicitly indicate a specific organization from which
participants were obtained.
Other – The sample of participants was obtained from a source other than those presented here
Sample Setting
The geographic location in which participants within a sample were retrieved. The
author’s/authors’ designation of one of the following:
Urban
Suburban
Rural
Urban-Suburban: reference must include both and only these terms
Urban-Rural: reference must include both and only these terms
Suburban-Rural: reference must include both and only these terms
Unclear: A statement that does not explicitly indicate a specific geographic location from which
participants were obtained.
Other: The sample of participants was obtained from a geographic location other than those
presented here.
Not Reported: The geographic location of participants was not reported.
Author’s Labeling of Participants
The diagnosis attributed to an individual participant or group. The author’s/authors’ designation
of one of the following:
Autism
Asperger
PDD-NOS
Unclear
Not Reported
Other
Severity of Participants Pre-Test
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The degree of severity associated with an individual participant’s or group diagnosis. The
author’s/authors’ designation of one of the following
Mild
Mild-Moderate: reference must include both and only these terms
Moderate
Moderate-Severe: reference must include both and only these terms
Severe
Unclear: A non-specific reference to multi-levels of severity (e.g., all levels of severity were
represented)
Mixed: reference to mild, moderate, and severe representation in the same group
Not Reported: The severity of participants was not reported.
Education Level of Participants
The level of education completed by an individual participant or group. The author’s/authors’
designation of one of the following:
Preschool
K-5
Middle School (6-8)
High School (9-12)
Home School
Clinic Only
Unclear: A statement that does not explicitly indicate the formal level of education of a
participant or group.
Other: The education level of a participant or group varied from those presented here.
Not Reported: The education level of participants was not reported.
Race/Ethnicity
The ethnic affiliation of an individual participant or group. The author’s/authors’ designation of
one of the following:
African American
American Indian
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Asian
Hispanic/Latino
White/Caucasian
Unclear: non-specific reference to multiple racial/ethnic group representation (e.g., “…several
race/ethnic groups were represented in the study.”)
Mixed: reference must include at least two specific race/ethnic group labels
Not Reported

Recruitment Pool
The method for identifying potential participants for assignment into groups.
Referral - Recommendation as participant(s) based on existing knowledge of participant
characteristics (e.g., physician referred).
Criterion - The participants are chosen based on specific characteristics (e.g., score less than a
specified cutoff score on a test administered before assignment).
Scores on norm referenced test- The participants are chosen based on scores reported on a norm
referenced test (e.g., Wechsler Intelligence Scale for Children).
Existing group - A group already together based on specific characteristics (e.g., outpatients from
a specialty clinic).
Volunteer - The participants offer themselves for inclusion in the study (e.g., respond to media
ad).
Waiting list – The recruitment pool is comprised of participants who have been on a waiting list
(e.g., waiting list for an intervention or program).
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Unclear - A statement that does not explicitly indicate the method of participant recruitment.
Not Reported - The method of participant recruitment was not reported.
Other – The method of participant recruitment varied from than those presented here.
Design Type
Randomized controlled trial (RCT) - Participants are randomly assigned to either experimental or
control groups. The researcher manipulates one or more independent variables and measures any
changes in the dependent variable(s) (Kerlinger & Lee, 2000, p. 491).
Quasi-experimental - Participants are not randomly assigned to either the experimental or control
group.
Subject Assignment
Individual random - "Assignment to experimental treatments of members of a universe in a
ways such that, for any given assignment to a treatment, every member of the universe has an
equal probability of being chosen for that assignment" (Kerlinger & Lee, 2000, p. 170). In short,
participants are randomly assigned to a condition.
Whole group random - Groups are randomly assigned to an experimental or control group. These
groups of participants are matched "in terms of overall distribution of the selected variable or
variables, rather than on an individual-by-individual basis" (Kerlinger & Lee, 2000, p. 491).
Individual matched-random - Participants are matched on one or more variables and then
randomly assigned to an experimental or control group. (Kerlinger & Lee, 2000).
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Matched non-random - Participants are matched on one or more variables, but not randomly
assigned to conditions.
Non-matched non-random - Participants are not matched on one or more variables and are not
randomly assigned to condition.
Unclear - A statement that does not explicitly indicate the method of subject assignment.
Not reported - Method of subject assignment was not reported.
Other - Assignment to condition(s) by any method other than those presented here.
Method of Random Assignment
Random number generation - Random assignment is utilized using a software program or
random number table.
Simple random - Random assignment within groups by participant characteristics (CONSORT
Statement, 2001).
Coin flip - Random assignment is completed by the flip of a coin.
Allocation/Assignment - The generation of an allocation sequence in which the number of
assignments to intervention groups satisfies a specified allocation ratio (such as 1:1 or 2:1) after
every "block" of specified size (CONSORT Statement, 2001).
Unclear - A statement that does not explicitly indicate the method of random assignment.
Other - Neither random number generated nor coin flip is used to complete the random
assignment.
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Not reported – The method of random assignment was not reported.
Type of Analysis
Intent to treat - Analysis of trial results which includes the data of all participants whether they
completed the treatment or not.
Treat only - Analysis in which only data from participants who completed the trial is used in the
final results.
Individual Blinding
Participants, caregivers, outcome assessors, and analysts are all potential candidates for
blinding. However, blinding of certain individuals may not be feasible (i.e., surgeons in surgical
trials). The author’s/authors’ assigned designation to the following:
Researcher
Participants
Intervener
Assessor
No Blinding
Unclear: A statement that does not explicitly indicate which individuals were blinded during the
study.
Not reported: Blinding during the study was not reported.
Group Blinding
The procedure of preventing those involved in a trial from knowing which comparison group a
participant belongs. The possibility of bias is reduced when as few people as possible know who
is receiving the experimental intervention or the control intervention.
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Open - In an open label experiment, both the researchers and participants are aware of which
treatment is being administered.
Single blinding - In a single blind experiment, the individual subjects do not know whether they
are members of a control group or members of an experimental group.
Double blinding - In a double-blind experiment, two parties do not know who belongs to the
control group and the experimental group.
Triple blinding – In a triple-blind experiment, three parties do not know which participants
belong to the control group and the experimental group.
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